Roivant Sciences Stock News

Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved cli...

Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved cli...

Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results for lung and swelling disease treatments.

Roivant said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with ​high blood pressure associated with a type of lung ‌disease, sending shares up about 20% in premarket trading.

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-...

BASEL, Switzerland and LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. The resu...

Roivant and partner Priovant Therapeutics on Friday set a list price of $35,000 for a ​30-day supply of their newly approved rare disease drug, ‌Lisraya.

The U.S. Food ‌and Drug Administration said on Thursday it approved a treatment from Roivant and ​partner Priovant Therapeutics for a ​rare disease, making it the ⁠first oral drug for the condition ​affecting skin and muscles.